COCA study

ABSTRACT: Interventions: The patients will use capecitabine in combination with 40 mg esomeprazole q.d. oral for four consecutive days (phase A and C) or capecitabine alone (phase B), while during phase C capecitabine is taken concomitantly with 250 ml Coca Cola. T Primary outcome(s): A relative difference in the AUC of at least 25% is considered to be clinically relevant (i.e. ratio of geometric means ≤0.75 or ≥1.33) and the within-patient standard deviation is assumed to be 27% Study Design: Randomized controlled trial, Open (masking not used), N/A , unknown, Crossover

DISEASE(S): Colorectal Carcinoma

PROVIDER: 21255 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR